Intimation about the date of the annual General Meeting

4% __ SANDU PHARMACEUTICALS LIMITED CIN:L24233GA1985PLC001587 SAP/DU W Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Ref: SPL/CORP-SEC/2026-27/BSE/169 Dated:11.08.2026 Bombay Stock Exchange Ltd, Phirojshah Jeejobhoy Towers, 25" Floor, Dalal Street, Mumbai 400 001 Manager-Department of Corporate affairs Sir, Sub: Outcome of the Board Meeting held on 11™ August 2026 with Scrip Code 524703. Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015 A Meeting of the Board of Directors of the Company duly convened on Tuesday, u* August 2026 at 04:00 p.m. and concluded at 5.15 p.m. discussed the following business: - 1. Financial Results Approved the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2026, as placed before the Board, along with the Limited Review Report thereon issued by the Statutory Auditors of the Company, expressing an unmodified conclusion. The said Unaudited Standalone Financial Results, together with the Limited Review Report, were duly considered, approved and taken on record by the Board of Directors. 2. Approved the Directors’ Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report and other reports forming part of the Annual Report of the Company for the financial year ended March 31, 2026, as placed before the Board. The Board duly considered and approved the same for inclusion in the Annual Report of the Company for the financial year 2025-26 and for circulation to the Members in connection with the ensuing Annual General Meeting. 3. Record Date Approved the closure of the Register of Members and Share Transfer Books of the Company from Friday, September 4, 2026 to Friday, September 11, 2026, both days inclusive, in connection with the ensuing Annual General Meeting of the Company. The Record Date for determining the eligibility of Members entitled to receive the proposed dividend for the financial year ended March 31, 2026 shall be Friday, September 4, 2026. 4. Took note of the Statement of Utilisation and Statement of Deviation(s) in utilisation of funds, if any, as required under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended June 30, 2026. AN 1SO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in &o 4% __ SANDU PHARMACEUTICALS LIMITED CIN:L24233GA1985PLC001587 SAP/DU Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. m Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in 5. Notice of Annual General Meeting Approved the convening of the 41st Annual General Meeting (“AGM”) of the Company to be held on Friday, September 11, 2026, at 4:30 P.M. (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”), in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. 6. Material Related Party Transactions Recommended the proposal for obtaining the approval of the Members at the ensuing Annual General Meeting for the continuation of the Material Related Party Transactions entered into/proposed to be entered into with M/s. Sandu Brothers Private Limited, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. The Board, after considering the relevant details and terms of the proposed transactions, recommended the same for approval of the Members at the ensuing Annual General Meeting. 7. Appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors of the Company for a first term of five consecutive years. The Board of Directors, based on the recommendation of the Audit Committee, approved and recommended the appointment of M/s. Dave & Dave, Chartered Accountants (Firm Registration No. 102163W), holding Peer Review Certificate No. 020259, as the Statutory Auditors of the Company for a first term of five consecutive years, commencing from the conclusion of the ensuing Annual General Meeting and continuing until the conclusion of the Annual General Meeting to be held in the year 2031, subject to the approval of the Members of the Company at the ensuing Annual General Meeting. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025- CFD-POD2/1/3762/2026 dated 30th January 2026 is disclosed as Annexure I. For Sandu Pharmaceuticals Limited Pratika Mhambray Company Secretary ACS :36512 Annexure I AN 1SO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in &o SANDU PHARMACEUTICALS LIMITED S/fF?p U CIN:L24233GA1985PLC001587 Do oe 8 Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Disclosure of information pursuant to Regulation 30 of SEBI isting Obligations and _ Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/1/3762/2026 dated 30th January 2026 Sr No Particulars Details 1. Reason for change viz. Appointment of statutory auditor for first term of appointment, resignation; 05 years Completion of theirterms Date of appointment/ Cessation Date of Reappointment 11.08.2026 Term of appointment: For a period of five (5) consecutive financial years commencing from Financial Year 2026-27 to Financial Year 2030-31, subject to approval of the Members at the ensuing Annual General Meeting and to hold office until the conclusion of the Annual General Meeting to be held in the year 2031. Brief Profile (in case of M/s. Dave & Dave, Chartered Accountants, is a appointment); partnership firm established in 1989 and registered with the Institute of Chartered Accountants of India (ICAI) under Firm Registration No. 102163W. The firm is based in Mumbai and has 2 partners, 2 associates and 10 other staff members. The firm has a valid Peer Review Certificate No. 020259, valid from 25 March 2025 to 31 March 2028. The firm has extensive experience in statutory, internal, management, stock and tax audits, along with services relating to corporate law and secretarial compliances, taxation, project financing, accounting and valuation. The partners of the firm have significant professional experience, with experience ranging from 25 to 35 years in taxation, audit, project finance and GST audit. The firm has also rendered professional services to various listed companies, private companies, public sector undertakings and banking institutions. Disclosure of relationships Ms. Dave & Dave, Chartered Accountants, is not between directors. (in case of related to any of the Directors or Key Managerial Appointment ) Personnel or Promoters and Promoter group of the Company AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in £ SANDU PHARMACEUTICALS LIMITED SAMD‘U CIN:L24233GA1985PLC001587 m Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in FOR SANDU PHARMACEUTICALS LIMITED. Pratika Mhambray Company Secretary ACS : 36512 AN 15O 9001:2015 CER [Showing first 8,000 characters — download PDF for full document]